U.S. Marine and Shipping Stock News

Coinbase Global stock snapshot after recent performance Coinbase Global (COIN) has seen mixed share performance recently, with a 4.3% one day decline and a 14.6% drop over the past week, in contrast with gains over the past month. See our latest analysis for Coinbase Global. At a share price of US$173.38, Coinbase Global’s short term share price return has weakened with a 14.6% decline over the past week, while the 3 year total shareholder return of 170.23% points to a very different long...

Recent legal action against Kyndryl Holdings (KD) has expanded securities class allegations around the company’s past free cash flow disclosures, and fresh internal control concerns together with SEC document requests are now sharpening investor focus on risk. See our latest analysis for Kyndryl Holdings. The legal and internal control issues arrive after a sharp reset in sentiment, with a 30 day share price return of 10.04% following a 90 day share price return decline of 52.90% and a 1 year...

If you are wondering whether Janus Henderson Group at around US$51.39 is offering fair value or hiding a margin of safety, the starting point is understanding what the current market price is really implying. The stock price has been steady over the last 7 days, with returns of 0.0%, while the 30 day return is 3.3%, the year to date return is 7.6%, and the 1 year return is 42.8%. This gives useful context before testing how those moves stack up against the underlying valuation. Recent...

Genius Sports (GENI) has moved closer to the center of sports advertising after expanding its Moment Engine across partners that the company says cover about 90% of the programmatic ad market, ahead of major global tournaments. See our latest analysis for Genius Sports. Despite the expanded reach of Moment Engine and new partnerships with agencies, broadcasters and the Pac-12, Genius Sports’ recent share price performance has been weak. The 30 day share price return is 24.49% and the 1 year...

Wondering if Celsius Holdings at around US$35.59 is a bargain or already pricing in a lot of optimism? This article walks you through the key signals behind the current price. The stock has had a choppy spell, with a 17.2% decline over the last 7 days, a 29.8% decline over 30 days, and a 25.5% decline year to date, even though the 1 year return sits at 1.3% and the 3 year and 5 year figures are 16.8% and a very large gain respectively. Recent coverage has focused on Celsius Holdings as a...

IBM (NYSE:IBM) and research partners report a quantum computing breakthrough, using current hardware to simulate real magnetic materials. The quantum simulations align with neutron scattering experiment data, indicating practical scientific use for existing quantum systems. The work points to potential applications in materials science, energy research, and medicine that are difficult to study with classical computers. For investors following NYSE:IBM, this update sits at the intersection...

Why Berkshire Hathaway is on investors’ radar today Berkshire Hathaway (BRK.B) is drawing fresh attention after recent share price softness, with the stock showing negative returns over the past month, past 3 months, year to date, and over the past year. For investors, that pullback, alongside a market value of about US$1.03b and a broad mix of operating businesses and investments, raises questions about how to think about Berkshire’s scale, recent financial trends, and current valuation. See...

Earlier this week, Arm Holdings unveiled the Arm AGI CPU, its first Arm-designed AI data center chip built on Neoverse CSS V3, marking the company’s move from pure IP licensing into supplying production silicon alongside partners such as Meta. This shift positions Arm closer to its hyperscale customers’ infrastructure spend, potentially altering how it earns revenue from AI workloads and custom silicon over time. We’ll now examine how Arm’s entry into selling its own AGI CPU silicon could...

Becton Dickinson recently presented at the 2026 Life Science Intelligence Summit and secured FDA 510(k) clearance for its Surgiphor 1000mL antimicrobial irrigation system, underscoring its push into specialized medtech solutions following the spin-off of its Biosciences and Diagnostics Solutions business. These moves highlight Becton Dickinson’s effort to reposition itself as a focused medical technology company built around innovation and productivity, even as analysts flag softer revenue...

If you are wondering whether Tronox Holdings is attractively priced or looking stretched, the recent share price moves give some important clues about where value might sit today. The stock last closed at US$9.01, with returns of 22.3% over 7 days, 25.8% over 30 days, 111.0% year to date and 31.8% over 1 year, while the 3 year and 5 year returns sit at 26.8% and 43.3% declines. Recent coverage has focused on how Tronox fits into the wider materials sector and what shifting expectations for...

What Aurinia Pharmaceuticals offers and where it stands today Aurinia Pharmaceuticals (AUPH) focuses on therapies for autoimmune diseases, anchored by its LUPKYNIS treatment for lupus nephritis. The company reported revenue of $283.055 million and net income of $287.202 million in the latest reported period. See our latest analysis for Aurinia Pharmaceuticals. Aurinia’s share price has been volatile in recent months, with a 1-day share price return of 1.60% and 7-day return of 3.77%, while...

In recent weeks, Axon Enterprise has seen strong demand for its AI-powered public safety tools and drones, alongside rising bookings for long-term contracts and mounting anticipation around an upcoming earnings release that analysts expect to show earnings per share growth. An interesting shift is how Axon’s expanding role in AI-driven situational awareness and defense-related applications is tying its growth prospects more closely to government spending priorities and conflict-related...

Viking Therapeutics (NasdaqCM:VKTX) has completed patient enrollment in its Phase 3 VANQUISH-2 trial for VK2735. The trial is evaluating VK2735, a dual GLP-1/GIP agonist, in obesity and type 2 diabetes. This milestone moves VK2735 further along Viking's clinical development path as of 2026. For you as an investor, the VANQUISH-2 enrollment milestone puts fresh attention on Viking Therapeutics, a clinical-stage company focused on metabolic and endocrine diseases. VK2735 sits within the...

Wondering whether SailPoint at US$12.28 is starting to look interesting or still too expensive for the risk you are taking. The stock has been under pressure, with a 0.5% decline over the last 7 days, 6.4% over the last month, and a year to date return of 35.2% and 40.2% over the past year. These moves are occurring as the market continues to reassess software names and focus more closely on business quality, balance sheet strength, and cash generation. For SailPoint, this context matters...

In March 2026, Organic Payment Gateways announced it now provides tested, specialized credit card processing integrations for Farm Bill-compliant US cannabis seed businesses using Wix e-commerce sites, bypassing restrictions from mainstream processors like Wix Payments, Stripe, and PayPal. The integrations pair high-risk-friendly merchant accounts with Authorize.Net and third-party carts while preserving existing Wix store designs, potentially making Wix a more practical option for regulated...

Wondering whether Western Alliance Bancorporation at around US$70 a share looks attractively priced or not? This article breaks down what the current valuation really implies for you as a shareholder or potential investor. The stock has moved 4.2% over the last week, while sitting on a 20.5% decline over 30 days and a 17.9% decline year to date, with an 8.2% decline over the last year and a very large 3 year return of around 2x. These swings have kept Western Alliance in the headlines, with...

Primerica stock snapshot after recent performance Primerica (PRI) has caught investor attention after mixed recent returns, with the stock roughly flat over the past month, a modest gain over the past week, and a negative total return over the past year. See our latest analysis for Primerica. At a share price of $253.69, Primerica has seen short term share price momentum cool, while the 1 year total shareholder return of 11.05% decline contrasts with 3 and 5 year total returns of 56.70% and...

Netflix raised subscription prices across all U.S. plans, including ad supported, standard, and premium tiers. The price change is tied to a broader content push into live events, live sports, video podcasts, and original programming. This is the first broad price adjustment since January 2025 and reflects a shift in how Netflix is approaching monetization and growth. Netflix, NasdaqGS:NFLX, is trading at $93.32, with the share price broadly flat over the past year at a 0.1% decline. Over...

If you are wondering whether American Public Education at about US$57.42 still offers value or has run too far ahead of itself, you are not alone. The stock has posted returns of 5.3% over 7 days, 26.3% over 30 days, 58.8% year to date and 148.2% over 1 year. Over 3 years the gain is around 11x and over 5 years it is 58.2%. Recent coverage around American Public Education has focused on how the business is positioned within the Consumer Services sector and how its model responds to changing...

Parker-Hannifin Corporation recently disclosed that long-serving director Kevin A. Lobo will not stand for reelection at the 2026 Annual Meeting, following his election to the Board of GE HealthCare Technologies, although he will remain on Parker-Hannifin’s Board until his current term ends. This leadership change comes as Parker-Hannifin’s Aerospace Systems segment reports record quarterly revenue and operating margins supported by a multi-billion-dollar backlog, highlighting both...

If you are wondering whether IDEXX Laboratories at around US$573 per share still makes sense for your portfolio, the key question is what you are actually paying for the underlying business. The stock has delivered a 35.7% return over the last year, even as the share price shows a 1.1% decline over 7 days, an 11.7% decline over 30 days, and a 14.4% decline year to date. These shifts can change how investors think about both upside and risk. Recent coverage has focused on IDEXX Laboratories...

Index inclusion puts EMCOR Group (EME) on more investors’ radar EMCOR Group (EME) was added to the FTSE All-World Index in March 2026. This inclusion can attract fresh demand as index funds and institutional investors adjust their holdings. See our latest analysis for EMCOR Group. Despite a recent 1-day share price decline of 5.03% and a 30-day share price decline of 9.98% to US$726.31, EMCOR’s 1-year total shareholder return of 91.87% and 5-year total shareholder return of about 5.5x suggest...

In February 2026, Raymond James upgraded The Baldwin Insurance Group Inc. to a strong Buy rating after the company delivered its sixth consecutive year of leading industry organic growth, margin expansion, and robust adjusted diluted earnings per share. At the same time, Baldwin Insurance Group authorized a US$250,000,000 share repurchase program over the next 12 months, signaling management’s confidence in the business and capital allocation priorities. We’ll now examine how Baldwin...

Q4 Earnings Put Elevance Health (ELV) in Focus Elevance Health (ELV) moved back into the spotlight after reporting fourth quarter and full-year 2025 results, highlighting Medicaid and Medicare Advantage pressures alongside Health Benefits revenue growth and a 2026 adjusted EPS target of at least $25.50. See our latest analysis for Elevance Health. At a share price of US$294.25, Elevance Health has seen a 10.05% 1 month share price decline and a 16.94% year to date share price decline, while...